All companies › CUE

CUE · Cue Biopharma, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells4
Research cases0
Last filing2026-10-12

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-12 — Ray Sumita · sold 1,844 @ $28.05 2026-10-12 — Lin Shao-Lee · sold 10,000 @ $27.50 2026-10-12 — Lin Shao-Lee · sold 1,087 @ $28.05 2026-10-12 — Meluzio Michael Vincent · sold 1,144 @ $28.05
2026-10-122026-10-12

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Lin Shao-Lee Chief Executive Officer, Director
Ray Sumita Chief Legal Compliance Officer, Corporate Secretary
Meluzio Michael Vincent VP, Prin. Accounting Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $CUE is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-12', 'insider_name': 'Ray Sumita', 'insider_title': 'Chief Legal Compliance Officer, Corporate Secretary', 'transaction_type': 'Open-market sell', 'shares': 1844.0, 'price': 28.05, 'value': 51724.2, 'is_buy': False}, {'transaction_date': '2026-10-12', 'insider_name': 'Lin Shao-Lee', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 10000.0, 'price': 27.5, 'value': 275000.0, 'is_buy': False}, {'transaction_date': '2026-10-12', 'insider_name': 'Lin Shao-Lee', 'insider_title': 'Chief Executive Officer, Director', 'transaction_type': 'Open-market sell', 'shares': 1087.0, 'price': 28.05, 'value': 30490.35, 'is_buy': False}, {'transaction_date': '2026-10-12', 'insider_name': 'Meluzio Michael Vincent', 'insider_title': 'VP, Prin. Accounting Officer', 'transaction_type': 'Open-market sell', 'shares': 1144.0, 'price': 28.05, 'value': 32089.2, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for CUE today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.